(CMPS) COMPASS Pathways plc Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CMPS) COMPASS Pathways plc Complete Analysis Pack
COMPASS Pathways Business Model Canvas: Strategy in Focus
Discover how COMPASS Pathways plc turns its pioneering mental health research into a scalable business model. This Business Model Canvas breaks down the company’s key partners, value proposition, customer segments, and revenue logic in a clear, practical format. Get the full version to unlock deeper strategic insight and make smarter investment or planning decisions.
Partnerships
Clinical trial sites in UK and US
COMPASS Pathways plc relies on UK and US clinical trial sites for COMP360, with Phase 2b treatment-resistant depression work and Phase 2 PTSD studies run across both markets. These sites handle screening, dosing, psychotherapy support, and follow-up visits; in 2024, COMPASS reported $130.9m in cash and cash equivalents, helping fund this trial network.
Contract research organizations
COMPASS Pathways plc relies on contract research organizations to run its 2 Phase 3 COMP360 studies, covering site management, monitoring, and endpoint data capture. That outside support helps a small clinical-stage Company keep timelines tight and lowers the fixed operating load while trials stay multi-site.
GMP manufacturing partners
COMPASS Pathways plc relies on GMP manufacturing partners to make COMP360, its 25 mg synthetic psilocybin, under controlled quality systems so each batch is produced, tested, and released the same way. That matters because investigational medicine trials need tight batch-to-batch consistency and reliable supply continuity across Phase 3 work.
Academic psychiatry collaborators
Academic psychiatry collaborators give COMPASS Pathways plc trial-design depth and scientific credibility, especially for COMP360 in treatment-resistant depression and PTSD. They help set endpoints, choose patients, and judge outcomes, which matters when late-stage programs must turn clinical data into clear evidence.
- Shape trial endpoints
- Refine patient selection
- Support result interpretation
Regulators and ethics committees
Regulators and ethics committees are core partners for COMPASS Pathways plc because psilocybin trials need approval before dosing and monitoring during the study. Its Phase 3 COMP005 enrolled 233 adults with treatment-resistant depression, and every step had to clear safety, consent, and protocol review.
These checks protect participants and keep the data usable for future filings with health authorities.
- Approval first, oversight throughout
- Review safety, consent, conduct
- Required for all human trials
Compass Pathways’ Trial Network Powers COMP360 Phase 3
COMPASS Pathways plc depends on UK and US trial sites, CROs, GMP makers, and academic psychiatry teams to run COMP360 studies in treatment-resistant depression and PTSD. These partners support screening, dosing, psychotherapy, monitoring, and endpoint capture across Phase 3 work.
Regulators and ethics committees are also core partners, since every psilocybin trial needs approval and ongoing oversight.
| Partner | Role |
|---|---|
| CROs | Run Phase 3 ops |
| GMP makers | Supply COMP360 |
| Sites | Dose and follow up |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of COMPASS Pathways plc, covering its psychedelic therapy strategy, partners, channels, revenue logic, and key risks.
Customizable Excel Spreadsheet
Clarifies COMPASS Pathways plc’s business model pain points in one editable, board-ready snapshot.
Reference Sources
Provides a credible source trail for COMPASS Pathways plc, helping stakeholders verify claims quickly and make better decisions.
Activities
Phase IIb TRD development
COMP360 is COMPASS Pathways plc’s lead proof point: its Phase IIb trial in treatment-resistant depression enrolled 233 adults and showed a 6.6-point MADRS advantage at week 3 for the 25 mg dose versus placebo. This program anchors most of the scientific and regulatory work, and it shapes the next-stage data package.
Phase II PTSD trials
COMPASS Pathways plc is running Phase II PTSD trials for COMP360, extending psilocybin beyond depression and building a second major clinical data package. The work matters because PTSD affects about 5% of adults in a given year, and positive Phase II data could widen the company’s market beyond its lead depression program.
Clinical operations management
COMPASS Pathways plc clinical operations management runs site activation, patient recruitment, supervised dosing, and follow-up in tightly controlled psychiatry trials. In 2025, its phase 3 program kept these steps central because each dosing day needs intensive monitoring, and delays directly hit speed, data quality, and trial cost.
CMC and quality control
CMC and quality control keep COMP360 consistent from batch to batch. The work covers manufacturing, chemistry, release testing, and supply-chain oversight, which matters because COMPASS Pathways plc is running 2 Phase 3 trials for a controlled psychedelic therapy product.
- Batch consistency
- Release testing
- Supply-chain control
- Supports Phase 3 scale-up
For COMPASS Pathways plc, this is a core operating task: without tight CMC control, dosing, safety, and trial integrity can break down.
Regulatory and scientific disclosure
COMPASS Pathways plc must file trial submissions, safety reports, and public readouts for its COMP360 program, then explain the data to investors and researchers. That disclosure work helps keep trial credibility high and supports capital access while the company advances late-stage development and manages a cash-intensive R&D model.
- File regulatory submissions on time
- Publish safety and efficacy data
- Brief investors and scientists
- Protect trial trust and funding access
COMPASS Pathways Advances Late-Stage Psilocybin Trials
COMPASS Pathways plc’s key work is running COMP360 late-stage clinical trials, with Phase IIb TRD data showing a 6.6-point MADRS edge at week 3 at 25 mg in 233 adults. It also expands psilocybin into PTSD, where about 5% of adults are affected yearly, while keeping dosing, safety follow-up, and site management tight.
CMC and quality control stay central because batch consistency, release testing, and supply-chain control support Phase 3 scale-up. Regulatory filings and data readouts keep trial trust and funding access intact.
| Key activity | Data point |
|---|---|
| Phase IIb TRD | 233 adults; 6.6 MADRS gain |
| PTSD program | About 5% annual prevalence |
| Phase 3 ops | 2 trials in 2025 |
Delivered as Displayed
Business Model Canvas
This preview shows the actual COMPASS Pathways plc Business Model Canvas you’ll receive after purchase, not a sample or mockup. The document is delivered exactly as displayed here, with the same structure, formatting, and content. Once your order is complete, you’ll get full access to this same ready-to-use file for editing, sharing, or presentation.
Resources
COMP360 psilocybin asset
COMP360 is COMPASS Pathways plc’s core investigational asset: a synthetic psilocybin therapy in clinical development for treatment-resistant depression. In its Phase 2b study, 233 adults were enrolled, and the 25 mg dose was the lead candidate, making COMP360 the main driver of future value creation if late-stage data support approval.
Phase IIb depression data
COMPASS Pathways plc’s 233-patient Phase IIb COMP360 trial in treatment-resistant depression is a core IP asset: it defined the 25 mg dose, key safety signals, and the MADRS endpoint used to shape Phase III and regulator talks. The readout also supported market confidence when the program showed a statistically significant symptom drop versus placebo.
PTSD development program
COMPASS Pathways plc’s PTSD development program adds pipeline depth beyond the lead treatment-resistant depression effort, with COMP360 already supported by 2 Phase 3 depression studies. It broadens the psychiatric market and builds more clinical evidence for the same psilocybin platform, which can raise the value of each new readout.
Specialist scientific team
COMPASS Pathways plc depends on a specialist scientific team in psychiatry, neuroscience, regulatory, and clinical development to run psychedelic medicine trials. That matters most in small clinical-stage biotech teams, where one Phase 3 study can involve 233 patients and heavy FDA and EMA oversight.
- Trial design and safety control
- Regulatory path for psychedelic therapy
- Small team, high specialist leverage
Public company capital base
As a listed plc on Nasdaq and the London Stock Exchange, COMPASS Pathways plc can raise capital through public equity markets, which is critical for a pre-revenue biotech that must fund long, expensive Phase 2 and Phase 3 trials. This capital base supports runway, trial execution, and regulatory work before any product sales begin.
- Public equity access lowers funding risk
- Cash supports multi-year R&D
- Best fit for pre-revenue biotech
COMP360 and Capital Access Power COMPASS Pathways' Late-Stage Push
COMPASS Pathways plc’s key resources are COMP360, its synthetic psilocybin IP, and the specialist clinical, regulatory, and psychiatry team needed to run late-stage trials. Its public listing on Nasdaq and the London Stock Exchange also supports access to capital for Phase 3 work.
| Key resource | Fact |
|---|---|
| COMP360 | Core investigational asset |
| Phase 2b trial | 233 adults enrolled |
| Late-stage pipeline | 2 Phase 3 depression studies |
| Capital access | Nasdaq and LSE listed |
Value Propositions
Investigational psilocybin therapy
COMP360 is COMPASS Pathways plc’s psilocybin-based therapy for treatment-resistant depression, built for supervised clinic use with trained clinicians, not self-dosing. That model sets it apart from standard antidepressants and fits a high-touch care pathway; COMPASS Pathways plc reported $132.5 million in cash and cash equivalents in its latest annual filing, supporting this clinical-development focus.
Treatment-resistant depression focus
COMPASS Pathways plc targets treatment-resistant depression, a high-need segment that affects about 30% of patients with major depressive disorder who do not respond adequately to prior care. Its Phase IIb program is built around this group, where unmet need remains high and new options can still change practice.
PTSD pipeline opportunity
COMPASS Pathways plc is extending COMP360 into post-traumatic stress disorder, adding a second psychiatric indication beyond major depressive disorder. PTSD affects about 13 million U.S. adults each year, so if the program works, it could expand the Company Name’s clinical reach and open a larger commercial market.
Controlled supervised treatment model
COMPASS Pathways plc uses a tightly supervised therapy model: in its 233-patient Phase 3 COMP360 trial for treatment-resistant depression, dosing was delivered in controlled clinical settings with trained staff, which supports safety checks and consistent care. That fits specialist psychiatric sites, where monitored administration and structured follow-up matter most.
- 233-patient Phase 3 trial
- Controlled dosing and monitoring
- Best fit: specialist psychiatry
Differentiated mechanism of action
COMP360 psilocybin uses a mechanism different from conventional antidepressants like SSRIs: it acts as a 5-HT2A receptor agonist, driving a psychedelic-assisted therapy model that targets hard-to-treat psychiatric illness. That differentiation is central to COMPASS Pathways plc’s thesis, backed by its 233-patient phase 2b TRD study and ongoing phase 3 program.
- Different from daily SSRIs
- Targets treatment-resistant depression
- Core to COMPASS Pathways plc thesis
Compass Pathways: Clinic-Based Psilocybin for Hard-to-Treat Depression
COMPASS Pathways plc’s value proposition is a supervised, clinic-based psilocybin therapy for treatment-resistant depression, aiming to serve patients who have not responded to standard care. Its edge is differentiation: a single, clinician-led dose model plus a broader pipeline in PTSD.
| Metric | Value |
|---|---|
| Phase 3 TRD trial | 233 patients |
| Latest cash | $132.5 million |
| Core use | Supervised clinic dosing |
Customer Relationships
Site-led clinical support
COMPASS Pathways plc runs site-led clinical support with hands-on training for investigators, coordinators, and therapists, because its psilocybin studies depend on tight protocol control and patient safety. This model helps keep study data consistent across trial sites and reduces dosing or therapy drift.
Clinician education
Future adoption of COMPASS Pathways plc’s psilocybin therapy will depend on training psychiatrists and specialist providers, since the company is running 2 Phase 3 trials and the treatment is delivered in controlled settings. Education must cover patient selection, administration, and monitoring, because safe use hinges on clinician skill, not just the drug itself.
Key opinion leader engagement
In FY2025, COMPASS Pathways stayed pre-revenue, so key opinion leaders like expert psychiatrists and researchers are central to validating COMP360, shaping Phase 3 trial design, and guiding how results are read. Their backing also helps push medical acceptance, which matters when there is still no commercial sales base.
Transparent scientific updates
COMPASS Pathways plc uses transparent scientific updates to keep investors aligned with its 2025-2026 clinical readouts, because public biotech firms must disclose trial progress through data releases, presentations, and SEC filings. For a clinical-stage psilocybin company, clear updates on Phase 3 work, safety signals, and endpoints help manage risk and trust.
- Regular trial updates
- Data at major medical meetings
- SEC filings for key changes
Investor relations
COMPASS Pathways plc keeps close contact with shareholders and potential investors, and that matters because its 2025 business was still pre-commercial, with no product sales. That investor tie-up helps fund long R&D cycles and the 2025 cash burn needed to push psilocybin programs toward late-stage data.
- Supports long R&D funding
- Critical before revenue starts
- Keeps capital markets engaged
COMPASS Pathways Builds Trust Around Phase 3 Execution
COMPASS Pathways plc keeps customer ties close to trial sites, KOLs, and investors, because its 2025 business was still pre-revenue and Phase 3 success depends on trust, training, and clean data. It backs this with regular scientific and SEC updates, plus site support for the 2 Phase 3 trials.
| Relationship | FY2025 data |
|---|---|
| Clinical sites | 2 Phase 3 trials |
| Revenue | Pre-revenue |
| Investor contact | SEC updates |
Channels
Clinical trial sites
Clinical trial sites are COMPASS Pathways plc’s main channel for screening, enrolling, and dosing patients in COMP360 studies. They remain the key access point until approval, with Phase 3 GEMINI-1 enrolling 233 patients, so site reach and investigator quality directly shape trial speed and execution.
Scientific conferences
COMPASS Pathways plc uses scientific conferences to present phase 2 and phase 3 data to psychiatrists, researchers, and investors, turning trial readouts into credibility. In biotech, this channel matters because major meetings can draw thousands of attendees and quickly build awareness before any product launch.
Peer-reviewed publications
Peer-reviewed publications are a core channel for COMPASS Pathways plc because they turn Phase 3 trial readouts into medical evidence that doctors and researchers can trust. In 2025, the company’s 2 pivotal COMP360 studies were designed to validate endpoints, safety, and study design, which helps drive scientific adoption and later guideline use.
Corporate website and investor materials
COMPASS Pathways plc uses its corporate website, SEC filings, and investor presentations to share trial updates, cash use, and pipeline progress with the market. For a listed clinical-stage company with no product revenue, these channels are the main way to build public disclosure and keep visibility across Nasdaq and the London Stock Exchange.
- Website: central update hub
- Filings: formal public disclosure
- Presentations: investor visibility
Regulatory submissions and trial registries
COMPASS Pathways plc uses health-authority filings and trial registries as a core channel for trial conduct, with each study tracked through status, design, endpoints, and results. These filings keep the Company aligned across jurisdictions and support transparent oversight for its late-stage psilocybin program.
- Tracks study status and outcomes
- Supports cross-border transparency
- Required for trial approval
How COMPASS Builds Trust: Trials, Conferences, and Filings
COMPASS Pathways plc’s main channels are clinical trial sites, where 233 patients were enrolled in GEMINI-1, plus conference presentations and peer-reviewed papers that turn Phase 2 and Phase 3 data into scientific trust. Its website, SEC filings, and investor decks keep markets updated, while trial registries and health-authority filings support oversight across jurisdictions.
| Channel | Role | Key data |
|---|---|---|
| Trial sites | Enroll and dose patients | GEMINI-1: 233 patients |
| Conferences and papers | Build medical credibility | 2 pivotal COMP360 studies |
Customer Segments
Treatment-resistant depression patients
Treatment-resistant depression patients are COMPASS Pathways plc’s lead target for COMP360: adults who have not improved after at least 2 antidepressant treatments. TRD affects about 30% of people with major depressive disorder, making this the company’s most advanced clinical market and its core path to value creation.
PTSD patients
COMPASS Pathways plc is testing its PTSD program in mid-stage clinical development, so it targets a large, underserved psychiatric group before late-stage proof. PTSD affects about 6% of U.S. adults at some point in life, and a successful readout could widen the addressable market beyond depression.
Psychiatrists and specialist clinicians
Psychiatrists and specialist clinicians are COMPASS Pathways plc's key prescribers and therapy supervisors if COMP360 is approved. They need training, clear protocols, and trial evidence to manage the estimated 280 million people living with depression worldwide, making them a core decision-making segment.
Hospitals and specialty mental health clinics
Hospitals and specialty mental health clinics are the main delivery sites for supervised psychedelic therapy, because they already have trained staff, monitoring, and clinical infrastructure for long dosing sessions that can run 6-8 hours. This segment is key for real-world rollout, where controlled settings matter more than scale alone.
- Staffed for continuous supervision
- Built for medical monitoring
- Best fit for regulated rollout
For COMPASS Pathways plc, these sites are the first practical customer base for COMP360-style care models.
Payers and health systems
Reimbursement and access will decide whether Company Name’s therapy scales after approval, because payers and health systems will test both clinical value and total cost before broad coverage. This matters in a mental health market where 1 in 8 people live with a disorder, so downstream buyers can make or break uptake.
- Coverage follows value and cost proof.
- Health systems control patient access.
COMPASS Pathways: TRD Access Hinges on Payers and Care Channels
COMPASS Pathways plc’s core customer segments are adults with treatment-resistant depression, with psychiatry clinics and hospital sites as the main care channels. Payers and health systems are the gatekeepers: 280 million people live with depression worldwide, but broad use will depend on reimbursement and supervised delivery.
| Segment | Role | Key fact |
|---|---|---|
| TRD patients | Primary users | ~30% of MDD |
| Psychiatrists | Prescribers | Need training |
| Payers | Access gatekeepers | Coverage drives uptake |
Cost Structure
Clinical trial spending
Clinical trial spending is COMPASS Pathways plc's biggest cost, driven by patient recruitment, site fees, monitoring, and data analysis. Multiple Phase II programs, including COMP360 studies, keep R&D cash burn high, so trial timing and enrollment are the main swings in operating spend.
Manufacturing and CMC costs
COMPASS Pathways plc’s psilocybin supply depends on GMP-controlled production and CMC release, because each 25 mg COMP360 dose needs testing, packaging, storage, and batch approval. These costs support both investigational use in Phase 3 and future commercial supply, so manufacturing quality and yield directly affect unit cost and scale.
Personnel and stock-based compensation
COMPASS Pathways plc needs scientists, clinicians, regulatory staff, and corporate teams, so personnel is a core cost. Like most public biotechs, it also uses equity awards; that makes stock-based compensation a meaningful part of operating expense.
Regulatory and safety compliance
Regulatory and safety compliance is a fixed but rising cost line for Company Name: its 2025 work spans 2 Phase 3 studies, legal/ethics review, pharmacovigilance, and SAE reporting. More sites and countries mean more documents, oversight, and audit load, so these costs scale faster than simple trial count.
- 2 Phase 3 studies drive oversight.
- Costs rise with geography and sites.
- Includes reporting, ethics, and safety.
Public company overhead
COMPASS Pathways plc carries ongoing public-company overhead from Nasdaq listing, including audit, legal, reporting, and investor-relations work. For a U.S.-listed biotech, these fixed costs typically run in the mid-six figures to low single-digit millions each year, and they help keep capital access open while pressuring margins.
- Audit and SEC reporting never stop
- Investor relations supports fund raising
- Nasdaq status adds fixed overhead
- Costs rise with compliance complexity
COMPASS Pathways’ Phase 3 Trials Drive the Bulk of Its Cash Burn
COMPASS Pathways plc’s cost base is dominated by Phase 3 R&D, with 2 pivotal COMP360 studies driving site fees, monitoring, and data work. GMP psilocybin supply for the 25 mg dose adds CMC, testing, and batch-release costs, while staff, stock pay, and Nasdaq compliance keep fixed overhead high.
| Cost item | 2025 anchor | Why it matters |
|---|---|---|
| Phase 3 trials | 2 studies | Main cash burn driver |
| COMP360 dose | 25 mg | GMP testing and release |
Revenue Streams
No approved product sales yet
COMP360 is still investigational, so COMPASS Pathways plc has no approved product sales and no marketed-product revenue yet. That leaves funding tied to external capital, with the company still depending on cash from equity or other financing to keep trials and operations moving.
Public equity financing
As a listed clinical-stage biotech, COMPASS Pathways plc can raise cash by issuing shares, and this is a standard funding route for trial-heavy firms. That equity funding helps cover operating burn and late-stage study costs; in 2024, the Company was still pre-revenue, so public markets remained a key source of capital.
Potential licensing income
As a clinical-stage, single-asset biotech, COMPASS Pathways plc had no product sales in its latest filings, so licensing is a key non-dilutive route. Future deals could bring upfront cash, development milestones, and royalties; in biotech, royalties often run in the mid-single to low-double digits, but any income here depends on signed agreements.
Potential milestone receipts
Potential milestone receipts for COMPASS Pathways plc are tied to clinical, regulatory, or commercial triggers, so they can bring in non-dilutive cash without product sales. In 2025, that matters because COMPASS Pathways still has no approved product revenue, so each deal-linked payment can help fund its Phase 3 work and extend runway.
- Linked to trial, FDA, or launch events
- Not sales; cash comes by contract
- Receipt depends on progress and deal terms
Future COMP360 sales
If approved, COMP360 could create therapy revenue in specialist mental health clinics, with sales linked to controlled dosing, trained staff, and payer reimbursement. As of the latest filings, COMPASS Pathways plc still has no commercial product revenue, so this is the long-term upside of the model.
- Specialist clinic sales only
- Reimbursement is key
- No product revenue yet
COMPASS Pathways: No Sales Yet, Still Funded by Equity
COMPASS Pathways plc’s revenue streams are still pre-commercial: in 2025, it had no approved product sales, so there was no marketed-product revenue from COMP360. Cash still came from equity financing and could later come from licensing deals, milestone payments, and royalties if trials and approvals succeed.
| Stream | 2025 status |
|---|---|
| Product sales | 0 |
| Equity funding | Primary cash source |
| Licensing/milestones | Potential, not yet realized |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.